In 1990 Mr. Kirby acquired the rights to a pharmaceutical patent and raised the initial capital to form TransDermal Technologies, Inc. He proceeded to formulate the product, design packaging, arrange for manufacturing and marketed the product in Florida by direct sales to consumers and retailers. In 1994, he was contacted by another biochemist to begin investigating the possibilities of delivering drugs and hormones transdermally without a patch or other device. Mr. Kirby and he began a collaboration that produced the TDS® technology which received its first patents in 2002, 2004 and 2007 citing Kirby as primary inventor.
In 2001, Mr. Kirby formed the Langford Research Institute and initiated a fully funded academic and research collaboration with the William Harvey Research Institute at St. Bartholomew’s and Queen Mary’s Medical College, University of London. Mr. Kirby has personally directed the pre-clinical and clinical research efforts with the Harvey encompassing 19 trials of 17 varied compounds and 7 human trials. The trials support and validate the expanding scientific underpinnings of the TDS® technology and has Mr. Kirby has received publication credit for his contributions to the science.
Mr. Kirby is a cum laude graduate of the Florida State University’s College of Arts and Sciences where as a pre-medical student he was focused on the psychopharmacology of Reserpine and the Rauwolfia Alkyloids, and began post-graduate studies. He was elected to Phi Beta Kappa. He is a Paul Harris Sustaining Fellow of the Rotary International Foundation. He is a member of the American Chemical Society’s Medicinal Chemistry Division and The Phi Beta Kappa Society.
Mr. Kirby chairs the Life Sciences Strategic Steering Committee for the Business Development Board of Palm Beach County, is a founding member and Co-Chairman of the South Florida Biosciences Consortium, The Research Coast Steering Committee, and a Founding Advisory Board Member of the Jim Moran Institute for Global Entrepreneurship at Florida State University and a member of Enterprise Florida’s Life Science Roadmap Committee. He has been appointed by The Scripps Research Institute to serve as one of two non-faculty members of its NIH-mandated Institutional Bio-Safety Committee overseeing the research at the Florida Institute. In 2006, Mr. Kirby accompanied Gov. Jeb Bush on his final trade mission to the U.K. to support life sciences and nominated Gov. Bush to receive the William Harvey Medal for Distinguished Contributions to Life Sciences which was awarded to him in a ceremony at the Great Hall at St. Bartholomew’s Hospital in London. In March 2006, Mr. Kirby was appointed by Gov. Bush, and then re-appointed by Gov. Charlie Crist to serve as a District Trustee for Palm Beach Community College. Mr. Kirby serves as District Chairman for the 2008-2009 Academic Year. In addition he was appointed by the Palm Beach County Board of County Commissioners to the board of The Workforce Alliance of Palm Beach County. He also serves on the Education Commission of Palm Beach County.
Mr. Kirby was the Inaugural Recipient of the President’s Award for the Business Development Board of Palm Beach County in 2005-2006 and was named an Advancements in Health Care Hero by the Palm Beach County Medical Society in 2008.
Scientific Publications
Attributed:
U.S. Patent 6,444,234, September 3rd 2002
U.S. Patent 6,787,152, September 7th, 2004
U.S. Patent 7,267,829, September 11th, 2007
European Patents No. 1,094,781 – 18 Issued Member Country Patents
Study of a combined percutaneous local anaesthetic and the TDS system for venepuncture, Anaesthesia, 2006, 61, pages 123–126, doi:10.1111/j.1365-2044.2005.04432.x
Liquid Transdermal Drug Delivery: The State of the TDS® Art; Drug Delivery Report Autumn/Winter 2005, Technology Overviews; PharmaVentures Publications
Pharmacokinetic Assessment of a Novel Transdermal Testosterone Delivery System in Healthy Males, Poster presented to the Winter Meeting of the British Pharmacological Society, December 2006
A New Testosterone Transdermal Delivery System, TDS®-testosterone, Has Superior Pharmacokinetics Compared to an Existing Transdermal Preparation in Healthy Males, Poster presented to Joint Annual Meeting of the American Endocrine Society, Boston, MA June 2006
Correcting endogenous concentrations of testosterone influences bioequivalence and shows the superiority of TDS®-testosterone to Androgel®, International Journal of Clinical Pharmacology and Therapeutics, Vol. 47 – No.1/2009 pp TBD
A Randomised, Single-Dose, Two-Period, Cross-Over Pharmacokinetic Study to Compare TDS®-Diazepam with Rectal Diazepam in Healthy Adult Subjects; Poster Abstract, June 2008 – Submitted to Canadian Pharmacological Society, Publication pending
Unattributed:
A Topically Applied Quaternary Ammonium Compound Exhibits Analgesic Effects for Orthopedic Pain; Alternative Medicine Review, Volume 3, Number 5, 1998 – Research Role – Designed, Developed and Managed trial, ghost-authored article. Reprints show attribution.
Pharmacokinetics of a new testosterone transdermal delivery system, TDS® -testosterone in healthy males; British Journal of Clinical Pharmacology (BJCP) Volume 61, Number 3 March 2006, pps. 275-279; DOI:10.1111/j.1365-2125.2005.02542.x - Research Role – Produced trial, supervised chemistry, manufacturing and controls, co-authored article.
